Skip to main content

Peer Review reports

From: Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial

Original Submission
21 Dec 2020 Submitted Original manuscript
20 Jan 2021 Reviewed Reviewer Report
28 Feb 2021 Reviewed Reviewer Report
29 Mar 2021 Author responded Author comments - Sepehr Gohari
Resubmission - Version 2
29 Mar 2021 Submitted Manuscript version 2
26 May 2021 Reviewed Reviewer Report
27 May 2021 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
17 Jun 2021 Editorially accepted
30 Jun 2021 Article published 10.1186/s12872-021-02131-1

You can find further information about peer review here.

Back to article page